Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 28, 2016
Ascendance Biotechnology has announced the execution of an agreement with GE Healthcare providing Ascendance a right to manufacture, market and sell the GE Healthcare Cytiva® brand of human stem cell-derived heart muscle cells (“cardiomyocytes”) used...
read more
Ascendia Pharmaceuticals has entered into a collaboration with KC Pharmaceuticals for the development of five OTC sterile ophthalmic drop medicines.
read more
Monday, December 13, 2021
Ascensus Specialties announced its acquisition of Wychem Limited, a UK-based manufacturer of fine chemicals for pharmaceutical and specialty applications. This transaction complements Ascensus’ existing capabilities and reinforces the Company’s focus...
read more
Thursday, January 07, 2021
Ascentage announced its licensee, UNITY Biotechnology, has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema.
read more
Thursday, February 25, 2021
Notal Vision announced the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision Diagnostic Clinic to support AsclepiX’s AXT107 phase 1 clinical trial program.
read more
Monday, December 02, 2019
Ascletis Pharma has announced Ascletis XinNuo Medicine has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.
read more
Monday, November 23, 2015
Ash Stevens a provider of global contract pharmaceutical chemical development and API (Active Pharmaceutical Ingredient) manufacturing services, has announced that the U.S Food and Drug Administration (FDA) has approved ASI's facility in Riverview, ...
read more
Monday, February 11, 2013
Ash Stevens Inc. (ASI), a full service contract pharmaceutical manufacturer, is in the final stages of completing a multi-year, multi-million dollar expansion to its cGMP manufacturing facility in Riverview, Michigan. All construction on the project ...
read more
Tuesday, December 29, 2015
Ash Stevens’ Riverview manufacturing facility is pleased to announce it has been recognized for exemplary efforts in improving its environmental, health, safety and security (EHS&S) operations by the Society of Chemical Manufacturers and Affiliates (...
read more
(BUSINESS WIRE) – Ash Stevens, Inc., a leading provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, is pleased to announce receipt of a 2014 Lilly Global Supplier ...
read more
Wednesday, December 09, 2015
Ash Stevens' Riverview manufacturing facility has been recognized for exemplary efforts in improving its environmental, health, safety and security (EHS&S) operations by the Society of Chemical Manufacturers and Affiliates (SOCMA), a trade ...
read more
Wednesday, January 28, 2015
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved...
read more
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, announces the U.S. Food and Drug Administration (FDA) has approved ASI's ...
read more
ProBioGen announced that Asher Biotherapeutics has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
read more
Wednesday, December 04, 2019
Ashfield has announced the promotion of Greg Flynn to President of Ashfield Commercial and Patient Solutions and the appointment Colin Stanley as President of Ashfield Advisory.
read more